All In Biotech

NDA 021227 · Merck

Cancidas

Caspofungin Acetate · Intravenous

NovelPriority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jan 26, 2001

Approved uses

7

Original approval plus efficacy supplements

Registered trials

67

24 Phase 3, 3 recruiting

FAERS reports

4,741

4,443 serious, 1,687 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 11, 2024.

CANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) 1.1 Empirical Therapy for Presumed Fungal Infections in Febrile, Neutropenic Patients CANCIDAS ® is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.1 , 14.5) ]. 1.2 Treatment of Candidemia and Other Candida Infections CANCIDAS is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.2 , 14.5) ]. Limitations of Use: CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida . 1.3 Treatment of Esophageal Candidiasis CANCIDAS is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.3 , 14.5) ]. Limitations of Use: CANCIDAS has not been approved for the treatment of oropharyngeal candidiasis (OPC). In the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis, patients with concomitant OPC had higher relapse rate of the OPC [see Clinical Studies (14.3) ]. 1.4 Treatment of Invasive Aspergillosis in Patients Who Are Refractory to or...

Mechanism: Caspofungin is an echinocandin antifungal drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CANCIDAS · CASPOFUNGIN ACETATE 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued · TE AP
  • CANCIDAS · CASPOFUNGIN ACETATE 70MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Caspofungin" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective684
  • off label use252
  • death226
  • product use in unapproved indication210
  • pneumonia203
  • pyrexia197
  • septic shock197
  • sepsis192
  • febrile neutropenia170
  • multiple organ dysfunction syndrome151
  • respiratory failure131
  • renal failure129

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004157
2005138
2006129
2007170
2008143
2009146
2010142
2011186
2012177
2013171
2014221
2015249
2016258
2017314
2018359
2019364
2020282
2021213
2022205
2023187
2024220
2025181
2026129

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cancidas (Caspofungin Acetate)

2024 spending

$24K

Beneficiaries

n/a

29 claims

Per beneficiary

n/a

$114.67 per unit

View as table
YearSpending
2020$66,887
2021$45,309
2022$71,985
2023$55,072
2024$23,911

Part B: Cancidas* (Caspofungin Acetate*) · HCPCS J0637

2024 spending

$15K

Beneficiaries

21

239 claims

Per beneficiary

$710

2024 ASP limit $6.27 per unit

View as table
YearSpending
2020$23,480
2021$54,747
2022$29,172
2023$45,044
2024$14,909

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 149 on PubMed

Sponsor: Merck

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.